Utility of p53 Immunohistochemical Staining for Risk Stratification of Mantle Cell Lymphoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.p53 immunohistochemistry (IHC) accurately identifies TP53 mutations in mantle cell lymphoma (MCL), offering a cost-effective alternative to next-generation sequencing (NGS). This method aids in risk stratification for MCL patients.
Area Of Science
- Hematology
- Oncology
- Molecular Diagnostics
Background
- Inactivating TP53 mutations are linked to poor prognosis in mantle cell lymphoma (MCL).
- Next-generation sequencing (NGS) is standard for TP53 assessment, but p53 immunohistochemistry (IHC) offers an alternative.
- The utility of p53 IHC for evaluating TP53 status in MCL requires further characterization.
Purpose Of The Study
- To evaluate the concordance between p53 IHC and TP53 mutational status determined by NGS in MCL cases.
- To assess the potential of p53 IHC as an accurate, timely, and cost-effective tool for risk stratification in MCL.
Main Methods
- Analysis of 47 MCL cases with available TP53 NGS data.
- Correlation of NGS findings with p53 IHC results.
- Comparison of turnaround time and cost between NGS and p53 IHC.
Main Results
- Twenty-eight percent (13/47) of cases exhibited TP53 mutations via NGS.
- p53 IHC demonstrated good concordance with NGS, showing 85% sensitivity and 100% specificity.
- TP53-mutated MCL cases showed a higher incidence of SOX11-negative status (23% vs. 3%).
- NGS was approximately 30 times more costly and six times slower than p53 IHC.
Conclusions
- p53 IHC is a reliable method for identifying TP53 mutations in MCL, with high specificity and moderate sensitivity.
- p53 IHC can serve as an efficient and cost-effective tool for risk stratification in MCL patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
